Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BetterLife Pharma Inc C.BETR

Alternate Symbol(s):  BETRF

BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The Company also owns a drug candidate for the treatment of viral infections such as COVID-19. The Company’s subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.


CSE:BETR - Post by User

Comment by goldmikeon Dec 24, 2020 6:38am
190 Views
Post# 32176010

RE: 5$(Five) Plus +++

RE: 5$(Five) Plus +++

The #1 largest publicly traded psychedelic companyCompass Pathways (CMPS) finished today at a new all-time closing high of $59.20 per share! Its market caphas now reached $2.124 billionNUMI after its latest equity offering will have a market cap of approximately US$156.345 millionRevive Therapeutics (CSE: RVV)'s market cap based on its latest shares outstanding is US$132.52 million.

BETR's market cap after acquiring 100% of Transcend Biodynamics LLC is currently only US$65.45 millionwhen BETR has acquired important intellectual property that will immediately position BETR alongsideMindMed (MMEDF) at the forefront of efforts todevelop LSD based pharmaceutical treatmentsMMEDF is currently being valued above US$1 billionmaking it the second most valuable publicly traded psychedelic company after CMPS.

<< Previous
Bullboard Posts
Next >>